SEC 13F Intelligence

Managers / Q2 2020 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$1.7B
Q2 2020
Positions
32
Filings on Record
15
2019–present window
Filed
Aug 14, 2020
original filing

Summary

Consonance Capital Management LP reported $1.7B in U.S.-listed holdings across 32 positions for Q2 2020.

Its largest position, Mersana Therapeutics, represents 8.3% of the portfolio.

Compared with Q1 2020, the fund opened 12 new positions and exited 11.

Portfolio Metrics

Turnover
+34.2%
vs prior filed quarter
Top-10 Concentration
+58.9%
share of reported value
Largest Position
+8.3%
Mersana Therapeutics
New / Exited
12 / 11
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 70.2%Other: 29.8%
  • Common Stock · 70.2% · $1.2B
  • Other · 29.8% · $498M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MERSANA THERAPEUTICS INCNEW+5.90M5.90M+$138M$138M
MGNXMACROGENICS INCNEW+4.04M4.04M+$113M$113M
GNMKGENMARK DIAGNOSTICS INCNEW+6.89M6.89M+$101M$101M
ATARA BIOTHERAPEUTICS INCNEW+5.24M5.24M+$76M$76M
COMPUGEN LTDNEW+4.08M4.08M+$61M$61M
APREA THERAPEUTICS INCNEW+1.25M1.25M+$49M$49M
STXSSTEREOTAXIS INCNEW+3.66M3.66M+$16M$16M
HARPOON THERAPEUTICS INCNEW+844.2K844.2K+$14M$14M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

32 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MERSANA THERAPEUTICS INCCOM8.27%$138M5.90M
2KARYOPHARM THERAPEUTICS INCCOM7.37%$123M6.49M
3MGNXMACROGENICS INChistory →COM6.76%$113M4.04M
4GNMKGENMARK DIAGNOSTICS INChistory →COM6.08%$101M6.89M
5CHEMOCENTRYX INCCOM5.88%$98M1.71M
6AKBAAKEBIA THERAPEUTICS INChistory →COM5.72%$95M7.03M
7KDMNKADMON HLDGS INChistory →COM4.82%$80M15.71M
8CDNACAREDX INChistory →COM4.74%$79M2.23M
9CYTKCYTOKINETICS INChistory →COM NEW4.73%$79M3.35M
10ATARA BIOTHERAPEUTICS INCCOM4.57%$76M5.24M
11AUPHAURINIA PHARMACEUTICALS INChistory →COM4.50%$75M4.62M
12ASSEMBLY BIOSCIENCES INCCOM4.44%$74M3.18M
13KINIKSA PHARMACEUTICALS LTDCOM CL A4.34%$72M2.84M
14SRPTSAREPTA THERAPEUTICS INChistory →COM4.09%$68M425.7K
15OMEROMEROS CORPhistory →COM3.68%$61M4.17M
16COMPUGEN LTDORD3.67%$61M4.08M
17APREA THERAPEUTICS INCCOM2.91%$49M1.25M
18APTOSE BIOSCIENCES INCCOM NEW2.64%$44M6.97M
19LIMINAL BIOSCIENCES INCCOM2.12%$35M3.29M
20IVERIC BIO INCCOM1.42%$24M4.65M
21BLUBELLUS HEALTH INC NEWhistory →COM NEW1.19%$20M1.92M
22OVIDOVID THERAPEUTICS INChistory →COM1.14%$19M2.57M
23STXSSTEREOTAXIS INChistory →COM NEW0.98%$16M3.66M
24HARPOON THERAPEUTICS INCCOM0.84%$14M844.2K
25ACTINIUM PHARMACEUTICALS INCCOM0.78%$13M37.00M
26ARAVIVE INCCOM0.67%$11M964.5K
27AXOVANT GENE THERAPIESCOM0.62%$10M3.65M
28ADMAADMA BIOLOGICS INCCOM0.47%$8M2.66M
29SOLENO THERAPEUTICS INCCOM NEW0.40%$7M3.04M
30QUREUNIQURE NVSHS0.14%$2M50.0K
31APELLIS PHARMACEUTICALS INCCOM0.02%$327,00010.0K
32SILK RD MED INCCOM0.01%$209,0005.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.